Abbott Laboratories will announce its second-quarter 2025 results on July 17. Expected revenue is $11.07 billion, which is a 6.7% increase from last year. The anticipated earnings per share (EPS) is $1.25, showing a 9.6% growth compared to the previous year. The Medical Devices segment is expected to drive this growth, largely due to the increased use of continuous glucose monitors and cardiac devices. Recently, Abbott received approval for the Tendyne transcatheter mitral valve replacement system, which is an important development. The Established Pharmaceuticals Division is projected to see a 6.1% rise in revenue. This growth comes from strong sales in areas like gastroenterology and biosimilars, particularly in international markets. In the Nutrition sector, sales of the adult brand Ensure are expected to support revenue growth. Strong sales in infant and toddler nutrition brands are also anticipated, leading to a projected 4.3% rise in this segment. Abbott has an Earnings ESP of +0.96% and a Zacks Rank #2, indicating it is likely to exceed earnings estimates. Similar potential is noted for CVS Health, Cencora, and Cardinal Health, which are all set to release earnings soon. Abbott’s results on July 17 show positive signs: expected revenue of $11.07 billion indicates nearly a 7% increase from last year, while EPS is projected at $1.25—almost a 10% gain. This growth is not explosive but reflects steady progress in key areas. The Medical Devices segment stands out in this growth. The adoption of continuous glucose monitors and cardiac devices drives sales. The recent approval of their mitral valve replacement device offers long-term potential in cardiac care. Though such approvals don’t immediately impact earnings, they can positively influence future growth expectations. Abbott’s Established Pharmaceuticals Division is expected to see about a 6% rise in income, thanks to strong sales in digestive health and biosimilars, particularly in global markets. However, biosimilars can be affected by regional pricing and competition, so future conference insights or updated forecasts may reveal changes in short-term outlooks. In the Nutrition sector, strong consumer demand is key. Adult brands, particularly Ensure, are predicted to perform well. Much of the optimism also relies on their pediatric segment, which is generally stable and defensible. This leads to an expected 4% revenue increase in this category, but actual results will depend on inventory levels and market demand dynamics, which won’t be fully visible until Q3. The earnings surprise prediction (positive ESP of 0.96%) and current ranking suggest a strong chance that the actual figures will exceed consensus estimates. However, recent weeks have seen estimates firm up, reducing the margin for upside. Future results may be less surprising compared to previous quarters unless there are improvements in operational margins or regional sales. Abbott is not alone in expected earnings surprises. CVS and Cencora, known for distribution, are growing relevant in pharma earnings comparisons as they expand services. Cardinal Health might also surprise, but its sensitivity to generic pricing and product mix could lead to volatility after earnings. Observing reports closely can help identify trading opportunities based on deviations. This situation prompts us to focus not just on financial results but also on operational metrics within each division. Significant changes in margins in the devices and nutrition sectors may provide early signals about pricing pressures and cost management that could affect performance in the latter half of the year. If device sales exceed expectations but operating income does not, further investigation into supply chain costs or research and development expenses may be necessary. As July progresses, expectations are clearer. The devices segment offers a good lead indicator, but any updates should consider unit demand signals rather than just total sales. Unless there’s a change in guidance, any differences from consensus EPS estimates will be more critical for market positioning after the report.

here to set up a live account on VT Markets now